SAFFRON data de-risks global regulatory filings for Tagrisso+Orpathys in MET-driven post-Tagrisso EGFRm NSCLC, a high-unmet-need population. Watch for regulatory submissions in US/EU over next 6-12 months and potential peak sales contribution. The combination strengthens AstraZeneca's lung cancer franchise against competitive threats.
Price Chart
Executive Summary
AstraZeneca announced positive Phase III SAFFRON trial results showing Tagrisso plus Orpathys significantly improved progression-free survival (PFS) and overall survival (OS) vs chemotherapy in EGFR-mutated NSCLC patients with MET-driven resistance after Tagrisso progression. This is the first global Phase III to show both PFS and OS benefit in this setting, supporting global regulatory submissions and reinforcing Tagrisso's backbone role in EGFRm lung cancer.
Key Facts
- SAFFRON Phase III trial met dual primary endpoint of PFS and key secondary endpoint of OS with statistical significance and clinical meaningfulness vs doublet platinum-based chemotherapy.
- Trial enrolled 338 patients across 230 centers in 29 countries; patients had EGFRm NSCLC with high MET overexpression/amplification after progression on Tagrisso.
- Safety profile consistent with known profiles of each medicine; no new safety findings.
- Data to be presented at forthcoming medical meeting and shared with global regulatory authorities.
- Tagrisso plus Orpathys already approved in China for this indication based on SACHI Phase III; temporary authorization granted in Switzerland based on SAVANNAH Phase II.
- Orpathys is jointly developed by AstraZeneca and HUTCHMED and commercialized by AstraZeneca.
Financial Impact
Positive read-through for Tagrisso franchise (AstraZeneca's top-selling drug) and Orpathys; potential to address ~34% of Tagrisso progressors who develop MET-driven resistance; supports global label expansion and revenue upside.
Risk Factors
- Regulatory timelines and approval decisions outside China are uncertain.
- Competing MET-targeted therapies (e.g., amivantamab combinations) could limit market share.
- Pricing and reimbursement dynamics for combination therapy may affect adoption.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-007677 |
| Document: 0001654954-26-007677-index-headers.html | 0001654954-26-007677 |
| Document: 0001654954-26-007677-index.html | 0001654954-26-007677 |
| Document: 0001654954-26-007677.txt | 0001654954-26-007677 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 6-K | $161.85 $168.37 | ▲ +4.03% | ▲ +1.90% | $156.52 (−3.29%) |
Sep 14, 2026 18d ago | 6-K | $163.78 $168.10 | ▼ −2.64% | ▼ −2.53% | $156.52 (+4.43%) |
Sep 8, 2026 24d ago | 6-K | $160.04 $161.85 | ▲ +1.13% | ▲ +2.25% | $156.52 (−2.20%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $156.52 (−3.51%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $156.52 (−3.51%) |
Sep 1, 2026 4w ago | 6-K | $162.47 $156.94 | ▼ −3.40% | ▼ −3.49% | $156.52 (−3.66%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $156.52 (−3.51%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $156.52 (−3.51%) |
Sep 1, 2026 4w ago | 6-K | $162.47 $156.94 | ▼ −3.40% | ▼ −3.49% | $156.52 (−3.66%) |
Aug 31, 2026 4w ago | Court Ruling | $162.13 $159.95 | ▲ +1.34% | ▲ +1.20% | $156.52 (+3.46%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access